Interleukin-6 - Ajinomoto

Drug Profile

Interleukin-6 - Ajinomoto

Latest Information Update: 27 Apr 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ajinomoto
  • Class Antineoplastics; Interleukins
  • Mechanism of Action Immunomodulators; Interleukin stimulants; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Thrombocytopenia

Most Recent Events

  • 27 Apr 1998 Discontinued-II for Cancer in Japan (Unknown route)
  • 27 Apr 1998 Discontinued-II for Thrombocytopenia in Japan (Unknown route)
  • 23 Jul 1997 Phase-II clinical trials for Cancer in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top